Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.
The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy.
The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
As of February 27, 2026, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|